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Edited by Veli-Pekka LehtoAbstract We investigated the inhibitory mechanism of curcu-
min and its derivative (CHC007) against b-catenin/T-cell factor
(Tcf) signaling in various cancer cell lines. Curcumin is known to
inhibit b-catenin/Tcf transcriptional activity in HCT116 cells but
not in SW620 cells. To clarify the inhibitory eﬀect of curcumin
against b-catenin/Tcf signaling, we tested several cancer cell
lines. In addition, in order to verify the inhibitory mechanism,
we performed reporter gene assay, Western blot, immunoprecip-
itation, and electrophoretic mobility shift assay. Since inhibitors
downregulated the transcriptional activity of b-catenin/Tcf in
HEK293 cells transiently transfected with S33Y mutant b-cate-
nin gene, whose product is not induced to be degraded by ade-
nomatous polyposis coli–Axin–glycogen synthase kinase 3b
complex, we concluded that the inhibitory mechanism was re-
lated to b-catenin itself or downstream components. Western blot
analysis suggested that no change in the amount of cytosolic and
membranous b-catenin in a cell occurred; however, nuclear b-
catenin and Tcf-4 proteins were markedly reduced by inhibitors
and this lead to the diminished association of b-catenin with Tcf-
4 and to the reduced binding to the consensus DNA. In the pres-
ent study, we demonstrate that curcumin and its derivative are
excellent inhibitors of b-catenin/Tcf signaling in all tested cancer
cell lines and the reduced b-catenin/Tcf transcriptional activity is
due to the decreased nuclear b-catenin and Tcf-4.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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b-Catenin presents two diﬀerent facets. One aspect is that it
contributes to the cell–cell adhesion in cooperation with E-cad-
herin. b-Catenin associates with the cytoplasmic domain of
E-cadherin and a-catenin in order to link these proteins to
the actin cytoskeleton [1]. The other aspect is that it possesses
transcriptional activity in cooperation with T-cell factor (Tcf)/Abbreviations: Lef, lymphoid enhancer factor; Tcf, T-cell factor;
GSK3b, glycogen synthase kinase 3b; EMSA, electrophoretic mobil-
ity shift assay; APC, adenomatous polyposis coli; NSAID, non-ster-
oidal anti-inﬂammatory drugs
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doi:10.1016/j.febslet.2005.04.013lymphoid enhancer factor (Lef) transcription factor in a nu-
cleus [2]. Some of the genes activated by b-catenin/Tcf signal-
ing are c-jun, c-myc, ﬁbronectin, cyclin D1, and fra-1 [3–5].
b-Catenin is phosphorylated in the cytoplasm by Axin–ade-
nomatous polyposis coli (APC)–glycogen synthase kinase 3b
(GSK3b) complex and degraded by ubiquitin–proteasome
pathway [6]. If this complex is not formed in the cytoplasm
due to several possible causes, however, b-catenin is not de-
graded and enters the nucleus to transactivate the Tcf/Lef tran-
scription factor leading to upregulation of many genes
responsible for cell proliferation. Since the APC gene or the
GSK-3b phosphorylation site within exon 3 of the b-catenin
gene are mutated in many cancer cells including colorectal can-
cer, melanoma, hepatocellular carcinoma and gastric carci-
noma, the transcriptional activity of b-catenin is upregulated
in these cancer cells [7–9]. This means that the dysregulation
of b-catenin plays a crucial role in many cancer cells. Therefore
if b-catenins transcriptional activity can be markedly down-
regulated, tumor growth will be suppressed. However, there
exist few b-catenin inhibitors. Aspirin, one of the non-steroidal
anti-inﬂammatory drugs (NSAIDs) was reported to attenuate
b-catenin/Tcf signaling [10].
Curcumin, a dietary pigment responsible for the yellow color
of curry, has been used as a medicine for the treatment of
inﬂammatory conditions. It has anti-inﬂammatory and anti-
oxidant activity and this may contribute to chemopreventive
activity [11]. Furthermore, curcumin derivative studies have re-
cently been actively pursued [12–15]. However, there are two
contradictory assertions concerning curcumin as a b-catenin/
Tcf signaling inhibitor [16–18] leading to uncertainty as to
whether curcumin inhibits b-catenin/Tcf signaling or not. So
we performed luciferase assay to clarify the inhibitory eﬀect
of curcumin and its derivative in several cancer cell lines and
studied their inhibitory mechanism in cells. Our data suggests
that curcumin and its analog are good inhibitors of b-catenin/
Tcf signaling in gastric, colon and intestinal cancer cell lines
and that their inhibitory mechanism is related to the reduced
amount of nuclear b-catenin and Tcf-4 proteins.2. Materials and Methods
2.1. Cell lines and reagents
AGS (stomach, human), HCT116, SW480 and HEK293 cell lines
were derived from KCLB (Korean Cell Line Bank, Korea). Curcumin
was purchased from Acros Organics (2440 Geel, Belgium) and curcu-
min derivatives were synthesized by our lab. Stock solutions wereblished by Elsevier B.V. All rights reserved.
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FOPﬂash were provided by Hans Clevers via Bart O Williams and wild
(pcDNA b-catenin) and mutant b-catenin gene (pcDNA S33Y) were
provided by Eric R. Fearon.
2.2. Isolation of whole cell and nuclear extracts
Cells were trypsinized and whole cell protein was obtained by lysing
the cells on ice for 20 min in 700 ll of lysis buﬀer (0.05 M Tris–HCl,
pH 7.4, 0.15 M NaCl, 1% Nonidet P-40, 0.5 M PMSF 50 lg/ml apro-
tinin, 10 lg/ml leupeptin, 50 lg/ml pepstatin, 0.4 mM sodium ortho-
vanadate, 10 mM sodium ﬂuoride, and 10 mM sodium
pyrophosphate). The lysates were then sonicated for 20 s and spun at
15000 · g for 10 min, and the supernatant was saved. Protein determi-
nations were made using the method of Bradford. The nuclear pellets
were prepared by resuspending cells in 800 ll of lysis buﬀer (10 mM
HEPES, pH 7.8, 10 mM KCl, 2 mM MgCl2, and 0.1 mM EDTA),
placing them on ice for 15 min and then vigorously mixing after the
addition of 50 ll of 10% Nonidet P-40. After a 30-s centrifugation
(16000 · g, 4 C), the pelleted nuclei were resuspended in 120 ll of
extraction buﬀer (50 mMHEPES, pH 7.8, 50 mMKCl, 300 mMNaCl,
0.1 mM EDTA, and 10% glycerol) and incubated on ice for 30 min.
Nuclear extracts were stored at 70 C.
2.3. Isolation of cytoplasmic and membrane proteins
Cell pellets were suspended in 800 ll lysis buﬀer (see whole cell pro-
tocol) without Tween 20 detergent, pulse sonicated (1 s · 30) on ice,
and then spun at 100000 · g for 1 h. The supernatant (cytoplasmic
fraction) was saved at 70 C. The membrane pellet was resuspended
in 300 ll lysis buﬀer with 1% Tween 20 and sonicated for 5 s on ice.
After 20 min, cell debris was removed (15000 · g for 10 min), and
the supernatant was saved. Western analysis and immunoprecipitation
were performed as described below.
2.4. Immunoprecipitation
Nuclear lysates or cellular lysates were prepared and 1 ml lysates
were incubated with 5 ll primary antibody for 90 min at 4 C. 30 ll
protein A/G plus (Santa Cruz, USA) was added and the complex
was incubated at 4 C overnight. Wash pellet three times with high salt
buﬀer (1 M Tris–HCl, pH 7.4, 0.50 M NaCl, and 1% Nonidet P-40)
and three times with lysis buﬀer. The immunoprecipitated complexes
were released with 2· sample buﬀer for western analysis.
2.5. Western analysis
Western analysis for the presence of b-catenin, Tcf-4, and c-myc
was performed on the whole extract, cytosol/membrane, or nuclear
proteins from AGS, SW480 and HCT116. Whole cell, nuclear, cyto-
plasmic and membrane proteins were isolated as described above. Pro-
tein (20–100 lg) was mixed 1:1 with 2· sample buﬀer (20% glycerol,
4% SDS, 10% 2-ME, 0.05% bromophenol blue, and 1.25 M Tris–
HCl, pH 6.8) loaded onto a 12% SDS–PAGE gel, and run at 120 V
for 2 h. Cell proteins were transferred to nitrocellulose (ECL; amer-
sham, Arlington Heights, IL) for 3 h at 250 mA. Equal loading of
the protein groups on the blots was evaluated using Bradford assay
and Ponceau S staining (nucleus or membrane proteins) or b-actin
band (cytosol or whole extracts). The nitrocellulose was then blocked
with 5% milk in TBST overnight, washed 4 times, and then incubated
with the primary Ab (anti b-catenin, c-myc, and Tcf-4 antibody, Santa
Cruz Biotechnology, Santa Cruz, CA) for 2 h at room temperature.
The blots were washed four times with TBST and incubated for 1 h
with HRP-conjugated anti-IgG AB (Santa Cruz Biotechnology, Santa
Cruz, CA). Immunoreactive bands were developed using a chemilumi-
nescent substrate (WEST-ZOL plus, iNtRON BioTechnology, KOR-
EA). An autoradiograph was obtained with exposure times of 2 min
to 12 h.Fig. 1. Structures of curcumin and CHC007.2.6. Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from cells using easy-BLUE RNA Extrac-
tion Kit (iNtRON, Korea) according to the manufacturers instruc-
tions. For cDNA synthesis, 4 lg of total RNA were included in a
25 ll reaction volume by using oligo(dT) primers (iNtRON, Korea)
and Reverse Transcriptase (iNtRON, Korea) following the manufac-
turers instructions. For PCR, 1/25 of the reverse transcription reaction
mixture was ampliﬁed with 22 cycles for c-myc or 17 cycles for b-actin.To amplify c-myc and b-actin fragments, 12, 15, 17 and 22 cycles were
used to determine whether the DNA ampliﬁcation was linear. All PCR
products were analysed by electrophoresis on a 1.5% agarose gel and
photographed. The sequences of primers (Bionics, Korea) used in
the reverse transcriptase-polymerase chain reaction (RT-PCR) were
as follows:
b-actin: 5 0-TCATGAAGTGTGACGTTGACATCCGT-3 0 (sense) and
50-CCTAGAAGCATTTGCGGTGCACGATG-30 (antisense);
c-myc: 5 0-TGTCAAGAGGCGAACACACAACGTC-3 0 (sense) and
5 0-ATCTTTCAGTCTCAAGACTCAGCCA (antisense).
2.7. Electrophoretic mobility shift assay
Nuclear extract, prepared as described above, was incubated for
30 min at room temperature with inhibitors and 32P-labeled double
stranded oligomer probe (5 0-CCCTTTGATCTTACC-3 0). It was ana-
lyzed by nondenaturing 4% polyacrylamide gel electrophoresis in
0.5· TBE buﬀer at 100 V for 40 min. Gels were visualized by autoradi-
ography.
2.8. Transfection and luciferase assay
Transient transfection was performed using lipofectamine and plus
reagent (Invitrogen, USA). Brieﬂy, 6.5 · 105 cells (AGS, HEK293) or
1.0 · 106 cells (SW480) or 1.5 · 106 cells (HCT116) were, respectively,
seeded in the medium onto 60 mm dish. After 24 h, cells were transfec-
ted with 1.5 lg of the luciferase reporter constructs (TOPﬂash or FOP-
ﬂash, respectively) and 1.5 lg of b-galactosidase gene for
normalization. Especially, HEK293 cells were co-transfected with
one another gene, 1.0 lg pcDNA b-catenin or pcDNA S33Y gene.
After 3 h of posttransfection, inhibitors were added with medium con-
taining FBS. Cells were incubated for 24 h, lysed in Reporter lysis buf-
fer (Promega, USA) and collected for assays of luciferase and
galactosidase activity, respectively. The activity was normalized to b-
gal values and expressed as relative value compared with control.3. Results
3.1. Reporter gene assay with various cancer cell lines
The structures of curcumin and CHC007, curcumin deriva-
tive, are shown in Fig. 1. CHC007 is a synthetic inhibitor,
which was reported to suppress the binding of AP1 to consen-
sus DNA more eﬃciently than curcumin [15]. We tested AGS
gastric cancer cells (missense mutation of glycine to glutamic
acid at codon 34 in GSK3b phosphorylation sites), HCT116
(deletion of Ser 45 in b-catenin) and SW480 human colon can-
cer cells (inactivating mutation of the APC gene) [7,19,20] with
curcumin and CHC007 using luciferase assay to ascertain their
inhibitory activity against b-catenin/Tcf signaling (Fig. 2).
These cell lines have a constitutively active transcriptional
Fig. 2. Curcumin and its derivative inhibit the transcriptional activity of b-catenin/Tcf in various cell lines. AGS, SW480 and HCT116 cells were co-
transfected with reporter genes harboring Tcf-4 binding sites (TOPﬂash) or a mutant Tcf-binding site (FOPﬂash), respectively, and b-galactosidase
gene. Three hours post-transfection increasing amounts of curcumin (A) and CHC007 (B) as indicated were added to the cells. Luciferase activity was
determined 24 h post-transfection, normalized against values for the corresponding b-galactosidase activity. An equivalent volume of DMSO
substituted for curcumin or CHC007 was used as a vehicle control. Values represent means ± S.E.M. of four independent experiments.
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with the reporter plasmids TOPﬂash or FOPﬂash and pCMV-
b-galactosidase to normalize for transfection eﬃciency. Inhib-
itors were treated with successively increasing doses for 24 h.
As a result, we could prove that curcumin and its derivative
markedly suppressed the transcriptional activity of b-catenin/
Tcf in all cancer cell lines depending on the concentration
(Fig. 2). 20 lM curcumin and 100 lM CHC007 inhibited
b-catenin/Tcf signaling by 58–63% and 70–78%, respectively,
compared with the control in all cell lines. 10 lM curcumin,
however, upregulates b-catenin/Tcf signaling by about 20%
in AGS and HCT116 cells. This phenomenon that inhibitor
enhance the activity of its target protein, b-catenin/Tcf, at
low concentration also occurred to indomethacin [21]. The
resistance of cells against inhibitor may bring about this acti-
vation. Further study is needed to investigate the cause.
3.2. The inhibition of b-catenin/Tcf signaling is related to
b-catenin itself or downstream components
We also performed luciferase assay with HEK293 cells to
ascertain whether curcumin and its derivative inhibited b-cate-
nin/Tcf signaling via the b-catenin degradation machinery in a
cell or via its downstream components including b-catenin it-
self. Since HEK293 has little b-catenin/Tcf transcriptional
activity, it was transiently transfected with b-catenin gene
(wild) and was treated with inhibitors (Fig. 3A and C). Lucif-
erase activity was increased about 25-fold by b-catenin gene
transfection. However, incubation of the cells with inhibitors
diminished the b-catenin/Tcf activity dose correspondingly.
Next, we performed luciferase assay with the cells transiently
transfected with S33Y mutant b-catenin (Serﬁ Tyr), whose
product is not induced to be degraded by Axin–APC–GSK3b
complex. Luciferase activity was increased about 100-fold by
S33Y gene transfection (Fig. 3B and D). Likewise as for the
former case, in HEK293 cells transfected with S33Y, the lucif-
erase activity was decreased by curcumin to about 90% at7.5 lM and at 100 lM CHC007 to about 80%. These data
strongly suggest that the inhibition of b-catenin/Tcf signaling
by curcumin and its derivative has no connection with the
b-catenin degradation machinery, but is related to b-catenin it-
self or downstream components. We investigated the possibil-
ity that inhibitors reduces the amount of cellular b-catenin
proteins to inhibit b-catenin/Tcf signaling. Cells were incu-
bated on 100 mm dishes for 1 day and inhibitors were added
to the cells for 24 h and the cellular lysates were isolated for
Western blot with b-catenin antibody. Fig. 3E shows that cur-
cumin and CHC007 have no inﬂuence on the amount of cellu-
lar b-catenin products. Based on these results, in order to
investigate b-catenin itself or its downstream components, we
focused on the nucleus where b-catenin functions as a tran-
scription activator.
3.3. The binding of Tcf complexes to DNA is decreased by
curcumin and CHC007
The binding to DNA is the most important step for tran-
scription factor. Therefore we performed electrophoretic
mobility shift assay (EMSA) to investigate whether the binding
of Tcf complexes to DNA is decreased by inhibitor treatment
in cells. Addition of Tcf-4 antibodies to the shift experiment re-
sulted in the interference of the formation of DNA–protein
complex (Fig. 4A). Fig. 4C (lanes 8–10) shows that when ex-
cess unlabeled Tcf-binding oligonucleotide was competitive
with 32P-labeled Tcf-binding oligonucleotide, the retarded
bands disappeared. This result suggests that the shifted DNA
protein complex is speciﬁc for Tcf complexes binding to the
consensus DNA. AGS (B) and HCT116 (C) cells were treated
with inhibitors for indicated times and the nucleus was pre-
pared for EMSA. Fig. 4 shows that the binding of Tcf com-
plexes to DNA is decreased dependent on the duration of
treatment. Therefore we can infer that the decreased binding
to DNA results in the decreased transcriptional activity of b-
catenin/Tcf.
Fig. 3. The inhibition of b-catenin/Tcf signaling is not related to b-
catenin degrading machinery, Axin–APC–GSK complex. (A–D)
HEK293 cells were co-transfected with TOPﬂash, b-galactosidase gene
and pcDNA3.1 (vehicle) or pcDNA b-catenin (A,C) or pcDNA S33Y
(mutant b-catenin gene) (B,D) Three hours post transfection increasing
amounts of curcumin or CHC007 as indicated were added to the cells.
Luciferase activity was determined 24 h post-transfection, normalized
against values for the corresponding b-galactosidase activity. An
equivalent volume of DMSO substituted for curcumin or CHC007 was
used as a vehicle control. Values represent means ± S.E.M. of four
independent experiments. (E) HCT116 and SW480 cells were treated
with curcumin or CHC007 for 24 h and cellular extracts were prepared
for Western blot assay with b-catenin antibody. Inhibitors did not alter
the amount of cellular b-catenin proteins.
Fig. 4. The binding of Tcf complexes to DNA is decreased by
inhibitors. AGS cells (B) and HCT116 cells (C) were treated with
20 lM curcumin (B) or 100 lM CHC007 (C) for indicated times and
nuclear extracts were isolated. EMSA was performed with 2 lg nuclear
extracts from treated or untreated cells. Lanes 2–3 (A) shows that Tcf-
4 antibodies interfere with the formation of retarded band. Lanes 8–10
(C) show that 10-fold and 15-fold excess of unlabeled Tcf-binding
oligonucleotide used as a competitor inhibits the binding of the b-
catenin/Tcf to oligonucleotide containing Tcf-binding region. The
other lanes are the results of binding to an 32P-labeled Tcf-binding
regions. The longer the treatment time is, the stronger was the
inhibitory eﬀect of curcumin against the association of b-catenin/Tcf
with consensus DNA. C, Control.
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b-catenin with Tcf-4 in the nucleus
The association of b-catenin with Tcf-4 is required for its
proper signaling [22,23]. Tcf-4 and b-catenin were coimmuno-
precipitated by using an anti-Tcf-4 antibody and blotted with
anti- b-catenin antibody. We examined the possibility that the
suppressed association of b-catenin with Tcf-4 leads to the sup-
pressed b-catenin/Tcf signaling. AGS and SW480 cells were
treated with inhibitors, and nuclei were isolated. Fig. 5 shows
that a substantial level of b-catenin/Tcf complex exists in the
nucleus of untreated SW480 and AGS cells. However, inhibi-
tors suppressed the association of b-catenin with Tcf-4 depen-
dent on the duration of the inhibitor treatment (A) and on the
concentration (B).
3.5. The amount of b-catenin and Tcf-4 in the nucleus is
decreased by inhibitors, but the level of b-catenin in the
cytosol and membrane is unchanged
It is well known that Tcf signaling-activation results from
accumulation of nuclear b-catenin [24,25]. We examined the
possibility that the decreased formation of the b-catenin/Tcf
complex and the suppressed bindings to DNA results from
the decreased nuclear b-catenin products by inhibitors. Since
b-catenin is widely spread from the membrane to the nucleus,we prepared cell fractation following treatment of the cells with
inhibitors, and performed Western blot analysis to determine
the change in the amount of b-catenin in each fractation (Fig.
6). As a result, in the cytosol (A) and the membrane fraction
(B), the amount of b-catenin protein was not altered by inhib-
itors; however, the amount of b-catenin in the nucleus was
markedly decreased dependent on the concentration (C) and
on the duration of the treatment (D,E). In AGS, HCT116,
and SW480 cells, incubation of the cells with 20 lM curcumin
or 100 lM CHC007 for 24 h decreased the nuclear b-catenin
proteins. The breakdown of b-catenin by inhibitors, in com-
pared with the control, is not seen. The same investigation
was conducted on Tcf-4, the partner of b-catenin in the nucleus
(F–H). Interestingly, the quantity of Tcf-4 products in the nu-
cleus was also decreased by curcumin as for b-catenin. The
amount of cellular Tcf-4 proteins were also decreased (data
not shown). Therefore, we can conclude that the decreased
quantity of b-catenin and Tcf-4 in the nucleus caused by inhib-
itors results in the diminished association of b-catenin with Tcf.
Moreover, we can infer that the decreased binding to Tcf-4
binding sites, as demonstrated by EMSA, results from the
reduction of Tcf-4 proteins in nucleus.
Fig. 5. The association of b-catenin with Tcf-4 is decreased by
inhibitors. Curcumin (20 lM) was treated in AGS cells for indicated
times (A) and in SW480 cells with increasing doses for 24 h (B).
Nuclear extracts were prepared and immunoprecipitation was per-
formed with Tcf-4 antibody followed by immunoblotting with b-
catenin monoclonal antibody. 60 kDa unknown band was used as a
control.
Fig. 7. Curcumin downregulates the c-myc mRNA and protein. (A)
SW480 cells were treated with curcumin (20, 40 lM) for 5 h or 9 h, and
trypsinized to isolate RNA and we performed RT-PCR to study the
change of c-myc mRNA by curcumin. (B) HCT116 cells were treated
with curcumin (20 lM) or CHC007 (100 lM) for 24 h and we
performed Western blot with anti-c-myc antibody (67 kd). 80 and 49
indicate the protein markers of 80 and 49 kd, respectively.
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We performed RT-PCR with c-myc primer. It is well known
that c-myc is a b-catenin target gene [3]. Therefore, we hypoth-
esized that curcumin would downregulate the c-myc gene tran-
scription by inhibiting b-catenin/Tcf signaling. In SW480 cell,
as we expected, c-myc was downregulated by 20 lM curcumin
(Fig. 7A). The c-myc product was also analysed by Western
blot and it was also found to be reduced by curcumin and
CHC007 in HCT116 cells (Fig. 7B). These results indicate that
the functioning of b-catenin as a transcription activator is ren-
dered inoperative by inhibitors.Fig. 6. b-Catenin and Tcf-4 products in nucleus are decreased by inhibitors.
indicated times (D,E) and were trypsinized for preparing cell fractation; cy
loading of the lines, anti-actin was used for cytosol (A) or Bradford assay and
cell fractation was used for Western blot with anti b-catenin antibody (A–E) o
independently repeated experiments. C, Control; Cur, curcumin; C7, CHC004. Discussion
This paper presents two important ﬁndings. First, curcumin
and its analog, CHC007, are good inhibitors of the b-catenin/
Tcf signaling pathway. Bordonaro et al. [18] claimed that
curcumin does not inhibit the b-catenin/Tcf transcriptionalCells were treated with curcumin or CHC007 for 24 h (A–C, F–H) or
tosol (A), membrane (B), nucleus (C–H). To demonstrate equivalent
Ponceau S stain was used for membrane (B) and nucleus (C–H). Each
r with anti Tcf-4 antibody (F–H). All pictures are representative of two
7.
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downregulates b-catenins transcriptional activity in HCT116
intestine cancer cells inducing G2/M arrest. To resolve this
confusion, we tested several cancer cell lines, namely gastric,
intestine and colon cancer, with curcumin and CHC007. In
all cell lines tested, b-catenins transcriptional activity was sup-
pressed by inhibitors dependent on the concentration (Fig. 2).
Moreover, these materials strongly inhibited the b-catenin/Tcf
transcriptional activity in HEK293 cells transiently transfected
with the WT b-catenin gene (Fig. 3). Our results strengthen the
conclusion that curcumin is eﬀective in inhibiting b-catenin/Tcf
signaling, in agreement with the ﬁndings of Jaiswal et al. Sec-
ondly, this paper demonstrates that the inhibitory mechanism
of curcumin and CHC007 is related to the reduced amount of
b-catenin and Tcf-4 products in the nucleus. As the importance
of b-catenin as a cause of tumorigenesis increases, many more
studies on the b-catenin inhibitor and its inhibitory mechanism
are being conducted. Dihlmann et al. [26] reported that NSA-
IDs inhibit b-catenin/Tcf signaling by increasing stabilization
of phosphorylated b-catenin, and Nath et al. [27] reported that
nitric oxide-donating aspirin inhibits b-catenin/Tcf by disrupt-
ing the nuclear b-catenin–Tcf association. Epigallocatechin-3-
gallate was reported to inhibit the b-catenin/Tcf signaling in
HEK293 cells transiently transfected with b-catenin gene
[28]. Jaiswal et al. [16] reported that curcumin suppressed the
b-catenin/Tcf activity but they only investigated the conse-
quence of diminished b-catenin/Tcf transcriptional activity in-
duced by curcumin, not how curcumin conferred an inhibitory
eﬀect on cancer cells. In the ﬁrst place, in order to ascertain the
relevance to APC–Axin–GSK3b complex, we tested HEK293
transiently transfected with a constitutively active mutant of
b-catenin gene (pcDNA S33Y). Inhibitors suppressed the
S33Y b-catenin/Tcf signaling and this indicates that the mech-
anism is not related to the b-catenin degrading machinery, but
to b-catenin itself or to the downstream components of b-cate-
nin in this signaling. To uncover the precise inhibitory mecha-
nism, we performed EMSA. EMSA data show that the binding
of Tcf complexes to DNA is severely impaired by curcumin
and its derivative (Fig. 4). In addition, coimmunoprecipitation
of b-catenin and Tcf-4 using Tcf-4 antibody shows that the
association of b-catenin with Tcf-4 is blocked by inhibitors
(Fig. 5). From these data we conclude that the reduced bind-
ings to DNA and the reduced association of b-catenin with
Tcf-4 caused by curcumin leads to the inhibition of b-cate-
nin/Tcf signaling. To know the cause of the suppressed binding
to Tcf-binding element and the decreased association of b-cate-
nin with Tcf-4, we investigated the amount of b-catenin and
Tcf-4 in treated cells. b-catenin is distributed widely in a cell.
It is located at the membrane with a cell–cell adhesion function
and is also located in the nucleus functioning as a transcrip-
tional activator, so we performed Western blot with cell frac-
tation (Fig. 6). Western blot data showed that the amount of
b-catenin protein in the cytosol and membrane fraction was
not altered; however, the amount of b-catenin in the nucleus
is decreased markedly by inhibitors. This ﬁnding is very impor-
tant, for b-catenin must be in the nucleus to associate with Tcf-
4 upregulating the b-catenin/Tcf signaling. NSAID and nitric
oxide-donating aspirin were reported not to reduce the nuclear
b-catenin proteins; [10,27] however, our data strongly suggest
that curcumin and its analog suppressed b-catenin/Tcf signal-
ing by reducing the nuclear b-catenin proteins. In addition,
the amount of Tcf-4 products in the nucleus was also decreasedby curcumin and CHC007 (Fig. 6). This reduction of nuclear
b-catenin and Tcf-4 proteins results in the decreased binding
to DNA containing Tcf-binding element, as demonstrated by
EMSA, and results in the decreased association of b-catenin
with Tcf-4. Eventually, we could conclude that the reduction
of b-catenin and Tcf-4 in the nucleus is the root of the sup-
pressed b-catenin/Tcf signaling. Now we can postulate several
possibilities to account for the decreased nuclear b-catenin
product due to curcumin and CHC007. The ﬁrst possibility
is that nuclear b-catenin is degraded in nucleus, not in cytosol
via GSK3b phosphorylation, by curcumin and CHC007
through an unknown mechanism. Jaiswal et al. [16] reported
that b-catenin in cellular extracts is cleaved by caspase-3. How-
ever, our Western blot data showed that b-catenin in the nu-
cleus is not cleaved compared to the control. That is, the
caspase-3 cleaves the b-catenin in the cytosol or in the mem-
brane, not in the nucleus. This assumption is supported by
the data of Jaiswal et al. demonstrating that the damaged b-
catenin/Tcf signaling is not recovered by caspase-3 inhibitor,
Z-DEVD-fmk, which blocks the cleavage of b-catenin by cas-
pase-3. The second possibility is that b-catenin is exported to
the cytosol from the nucleus by curcumin and CHC007. It is
already well known that b-catenin is exported to the cytosol
from the nucleus by an APC-dependent or APC-independent
pathway, and that Lef-1 blocks the APC-mediated nuclear
export of b-catenin [29–31]. Curcumin and its derivative may
enhance the b-catenin exporting system. Further studies by
our group will focus on the b-catenin exporting pathway by
inhibitors.
In this regard, we assume that the antitumor activity of
curcumin occurs via the inhibition of the b-catenin/Tcf sig-
naling pathway by reducing the nuclear b-catenin and Tcf-
4 proteins. Based on these ﬁndings, therefore, if we can syn-
thesize more potent curcumin derivatives by applying the
tools of organic chemistry to inhibit b-catenin/Tcf signaling
with lower toxicity, we can achieve an excellent chemopre-
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